Inflammatory Bowel Diseases
Conditions
Brief summary
Mesalazine, steroid, immunosuppressants and biologic agents are main medical treatments in treating inflammatory bowel diseases. Yet some patients develop severe side effects or initial invalid to conventional therapies. Some studies have already showed that tarcolimus and methotrexate are both effective in inducing and maintaining disease remission. Here we conduct a retrospective study to compare the efficancy of tarcolimus and methotrexate in treating refractory inflammatory bowel diseases as rescue therapy.
Interventions
None listed
Sponsors
Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, China
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Tarcolimus or methotrexate was used in refractory inflammatory bowel disease patents
Exclusion criteria
* Pregnant woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease activity assessment after one year treatment | one year | Disease activity is assessed through blood test, radiology and clinical for both Crohn's disease and ulverative colitis. We evaluate clinical response based on Crohn's disease activity index (CDAI) for CD and Mayo score for UC at the end of one year observation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of participants require surgical intervention during treatment and the number of participants with treatment-related adverse events. | one year | The number of participants require surgical intervention during treatment and the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
China
Contacts
Primary ContactJun Shen, MD
Outcome results
None listed